Cargando…
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCR-ABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7–8 December 2010 in Orlando, Florida, USA. During this meeting, the mo...
Autores principales: | Tefferi, A, Abdel-Wahab, O, Cervantes, F, Crispino, J D, Finazzi, G, Girodon, F, Gisslinger, H, Gotlib, J, Kiladjian, J-J, Levine, R L, Licht, J D, Mullally, A, Odenike, O, Pardanani, A, Silver, R T, Solary, E, Mughal, T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255279/ https://www.ncbi.nlm.nih.gov/pubmed/23471017 http://dx.doi.org/10.1038/bcj.2011.4 |
Ejemplares similares
-
Targeting megakaryocytic induced fibrosis by AURKA inhibition in the myeloproliferative neoplasms
por: Wen, Qiang Jeremy, et al.
Publicado: (2015) -
Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
por: Begna, K, et al.
Publicado: (2016) -
AKT is a therapeutic target in myeloproliferative neoplasms
por: Khan, Irum, et al.
Publicado: (2013) -
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
por: Tefferi, A, et al.
Publicado: (2017) -
Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
por: Tefferi, A, et al.
Publicado: (2017)